Structural Biology in Drug Discovery

Structure-based drug discovery is now a full part of the pharmaceutical industry, and many companies use both high-throughput screening and fragment screening to find starting points for their small-molecule R&D programs.

Knowledge of the 3D structures of proteins has long been acknowledged as having the potential to expedite drug discovery, but recent advancements in genome sequencing, robotics, and bioinformatics have drastically altered the opportunities. Through genomic analyses and X-ray or NMR spectroscopy, numerous new protein targets have been found and examined. Structural biology has been essential in guiding not only lead optimization and target identification, where it has well-established responsibilities, but also lead discovery, now that high-throughput methods of structure determination may provide effective screening approaches.

Tags
Structural Biology Conferences Cell Signalling Conferences Genomics Conferences Structural Genomics Conferences Molecular Biology Conferences 2024 NMR Spectroscopy Conferences Protein Chemistry Conferences Mass Spectrometry Conferences Molecular Biology Conferences Structural Biology Conferences 2024 Europe Stereochemistry Conferences Protein Engineering Conferences cryo-EM Conferences Structural Biology Conferences 2024 USA Computational Structural Biology Conferences 2024

+1 (506) 909-0537